Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Platelet-activating factor antagonists.

R N Saunders, D A Handley

    Annual Review of Pharmacology and Toxicology
    |January 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Platelet-activating factor (PAF) is a key inflammatory mediator. New PAF receptor antagonists show promise for treating diseases like asthma and septic shock, though further research is needed.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Significance of R1 resection margin in colon cancer resections in the modern era.

    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2015
    Same author

    Closed cutaneous left iliac fossa mucus fistula after emergency subtotal colectomy.

    Annals of the Royal College of Surgeons of England·2007
    Same author

    An algorithm for the management of bile leak following laparoscopic cholecystectomy.

    Annals of the Royal College of Surgeons of England·2007
    Same author

    Heavy rectal bleeding secondary to the passage of a rectal leiomyoma per anus.

    Annals of the Royal College of Surgeons of England·2006
    Same author

    Antegrade porridge enema to assess anorectal function after severe perineal sepsis.

    Annals of the Royal College of Surgeons of England·2006
    Same author

    The pursuit of precision pharmaceuticals: divergent effects of beta2 agonist isomers.

    Expert opinion on investigational drugs·2005
    Same journal

    Navigating the Computational Landscape for Drug Repurposing.

    Annual review of pharmacology and toxicology·2026
    Same journal

    Microplastics and Atherosclerosis: Mechanisms.

    Annual review of pharmacology and toxicology·2026
    Same journal

    Treating Pregnant and Lactating Women: Insights from Clinical Pharmacology.

    Annual review of pharmacology and toxicology·2026
    Same journal

    <i>Caenorhabditis elegans</i> as a Model System for Environmental Mitotoxicants.

    Annual review of pharmacology and toxicology·2025
    Same journal

    Introduction to the Theme "New Approaches, Technology, and Techniques That Advance Pharmacology and Toxicology".

    Annual review of pharmacology and toxicology·2025
    Same journal

    A Mechanistic Framework for Repurposing FDA-Approved Drugs to Combat Antimicrobial Resistance: The Case of <i>Staphylococcus aureus</i>.

    Annual review of pharmacology and toxicology·2025
    See all related articles

    Area of Science:

    • Immunology
    • Pharmacology

    Background:

    • Platelet-activating factor (PAF) has emerged as a significant inflammatory mediator.
    • Recent research, publications, and meetings highlight its importance and suggest ongoing future studies.
    • The potential involvement of PAF in human diseases is increasingly recognized.

    Purpose of the Study:

    • To review the current understanding of PAF as an inflammatory mediator.
    • To discuss the challenges and progress in proving PAF's role in human diseases.
    • To explore the potential of PAF receptor antagonists in therapeutic applications.

    Main Methods:

    • Review of existing scientific literature on PAF and its antagonists.
    • Analysis of structure-activity relationships of PAF antagonists.
    • Discussion of the clinical implications and potential applications of PAF modulation.

    Related Experiment Videos

    Main Results:

    • PAF is a potent mediator involved in inflammation.
    • Developing PAF receptor antagonists is challenging due to low antagonist potency compared to PAF.
    • First-generation PAF antagonists are available, but require further development for specific clinical needs.

    Conclusions:

    • PAF is likely a key mediator in various poorly understood diseases, including transplant rejection and adult respiratory distress syndrome.
    • The development of selective PAF antagonists with varied delivery routes and half-lives is crucial for future therapeutic strategies.
    • Clinical validation is required to confirm the role of PAF and the efficacy of its antagonists in human diseases.